EPHX2 and cardiac hypertrophy: In a murine model of HF, treatment with sEH inhibitor, adamantan-3-(5-(2-(2-ethylethoxy) ethoxy) pentyl) urea (AEPU) to limit epoxylipid metabolism, prevented pressure-overload-induced cardiac hypertrophy and decreased susceptibility to ventricular arrhythmias.